SMARCB1 and rhabdoid tumor: Initial preclinical studies demonstrated that it induced apoptosis and differentiation in SMARCB1-deleted rhabdoid tumors in vitro and in vivo (215), with significant anti-tumor activity observed in rhabdoid tumor models, including AT/RT, but variable responses across other pediatric solid tumors (216).